DaVita Inc. provides kidney dialysis services for patients suffering from chronic kidney failure or end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also provides outpatient, hospital inpatient, and home-based hemodialysis services; owns clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers. In addition, the company operates DaVita Rx, a pharmacy that provides oral medications and medication management services to patients with ESRD; disease management services; vascular access services; clinical research programs; physician services; and direct primary care services. As of December 31, 2017, it provided dialysis and administrative services in the United States through a network of 2,510 outpatient dialysis centers serving approximately 197,800 patients; and operated 237 outpatient dialysis centers located in 11 countries outside of the United States. Further, the company provides acute inpatient dialysis services in approximately 900 hospitals and related laboratory services in the United States. The company was formerly known as DaVita HealthCare Partners Inc. and changed its name to DaVita Inc. in September 2016. DaVita Inc. was founded in 1994 and is headquartered in Denver, Colorado.
Industry, Sector and Symbol
Stock Exchange NYSE
Industry Miscellaneous health & allied services, not elsewhere classified
Sub-IndustryHealth Care Services
SectorMedical
SymbolNYSE:DVA
CUSIP23918K10
Phone303-405-2100
Debt
Debt-to-Equity Ratio1.94
Current Ratio2.94
Quick Ratio2.90
Price-To-Earnings
Trailing P/E Ratio21.54
Forward P/E Ratio17.53
P/E Growth1.05
Sales & Book Value
Annual Sales$10.88 billion
Price / Sales1.15
Cash Flow$7.7025 per share
Price / Cash9.31
Book Value$26.66 per share
Price / Book2.69
Profitability
EPS (Most Recent Fiscal Year)$3.32
Net Income$663.61 million
Net Margins2.94%
Return on Equity13.84%
Return on Assets3.61%
Miscellaneous
Employees74,500
Outstanding Shares174,500,000
Market Cap$12,523.86
Davita (NYSE:DVA) Frequently Asked Questions
What is Davita's stock symbol?
Davita trades on the New York Stock Exchange (NYSE) under the ticker symbol "DVA."
How will Davita's stock buyback program work?
Davita announced that its Board of Directors has authorized a stock repurchase plan on Wednesday, October 11th 2017, which allows the company to buyback $1,500,000,000.00 in outstanding shares, according to EventVestor. This buyback authorization allows the company to buy shares of its stock through open market purchases. Shares buyback plans are generally a sign that the company's board of directors believes its shares are undervalued.
How were Davita's earnings last quarter?
Davita Inc (NYSE:DVA) announced its quarterly earnings results on Thursday, May, 3rd. The company reported $1.05 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.92 by $0.13. The firm had revenue of $2.85 billion for the quarter, compared to analysts' expectations of $2.79 billion. Davita had a net margin of 2.94% and a return on equity of 13.84%. The business's revenue for the quarter was up 8.3% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.79 earnings per share. View Davita's Earnings History.
When is Davita's next earnings date?
What price target have analysts set for DVA?
11 Wall Street analysts have issued 1-year price targets for Davita's shares. Their forecasts range from $60.00 to $97.00. On average, they expect Davita's stock price to reach $81.1250 in the next twelve months. This suggests a possible upside of 13.1% from the stock's current price. View Analyst Ratings for Davita.
What is the consensus analysts' recommendation for Davita?
11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Davita in the last year. There are currently 4 hold ratings, 5 buy ratings and 2 strong buy ratings for the stock, resulting in a consensus recommendation of "Buy."
Who are some of Davita's key competitors?
Who are Davita's key executives?
Davita's management team includes the folowing people:
- Mr. Kent J. Thiry, Chairman & CEO (Age 62)
- Joel Ackerman, Chief Financial Officer (Age 53)
- Mr. James K. Hilger, Chief Accounting Officer (Age 56)
- Ms. Kathleen Alyce Waters, Chief Legal Officer (Age 50)
- Mr. Javier J. Rodriguez, Chief Exec. Officer of DaVita Kidney Care (Age 47)
Has Davita been receiving favorable news coverage?
Media coverage about DVA stock has been trending somewhat positive this week, Accern reports. The research firm identifies negative and positive news coverage by monitoring more than 20 million news and blog sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Davita earned a media sentiment score of 0.12 on Accern's scale. They also assigned media stories about the company an impact score of 46.14 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Davita's major shareholders?
Davita's stock is owned by many different of retail and institutional investors. Top institutional investors include Manning & Napier Group LLC (1.03%), Bank of Montreal Can (0.14%), DnB Asset Management AS (0.12%), Fjarde AP Fonden Fourth Swedish National Pension Fund (0.03%), State of Alaska Department of Revenue (0.02%) and CenturyLink Investment Management Co (0.01%). Company insiders that own Davita stock include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Michael David Staffieri, Pamela M Arway and William L Roper. View Institutional Ownership Trends for Davita.
Which major investors are selling Davita stock?
DVA stock was sold by a variety of institutional investors in the last quarter, including Manning & Napier Group LLC, DnB Asset Management AS, Bank of Montreal Can, Clinton Group Inc., Fjarde AP Fonden Fourth Swedish National Pension Fund and Gateway Investment Advisers LLC. Company insiders that have sold Davita company stock in the last year include Charles Berg, James K Hilger, Javier Rodriguez, Kent J Thiry, Leanne M Zumwalt, Pamela M Arway and William L Roper. View Insider Buying and Selling for Davita.
Which major investors are buying Davita stock?
DVA stock was bought by a variety of institutional investors in the last quarter, including CenturyLink Investment Management Co, Denali Advisors LLC, State of Alaska Department of Revenue, Atria Investments LLC, IFM Investors Pty Ltd and Vigilant Capital Management LLC. View Insider Buying and Selling for Davita.
How do I buy shares of Davita?
Shares of DVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Davita's stock price today?
One share of DVA stock can currently be purchased for approximately $71.71.
How big of a company is Davita?
Davita has a market capitalization of $12.52 billion and generates $10.88 billion in revenue each year. The company earns $663.61 million in net income (profit) each year or $3.32 on an earnings per share basis. Davita employs 74,500 workers across the globe.
How can I contact Davita?
Davita's mailing address is 2000 16TH STREET, DENVER CO, 80202. The company can be reached via phone at 303-405-2100 or via email at [email protected]
MarketBeat Community Rating for Davita (NYSE DVA)
MarketBeat's community ratings are surveys of what our community members think about Davita and other stocks. Vote "Outperform" if you believe DVA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe DVA will underperform the S&P 500 over the long term. You may vote once every thirty days.
